Are you Dr. Costello?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Brian Costello, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Connecticut, and Tennessee. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2009
University of New Mexico School of MedicineResidency, Internal Medicine, 1995 - 1998
Medical College of WisconsinClass of 1995
Certifications & Licensure
NH State Medical License 2013 - Present
AZ State Medical License 2013 - 2026
ND State Medical License 2014 - 2026
MT State Medical License 2014 - 2026
MI State Medical License 2013 - 2026
WI State Medical License 2013 - 2025
MN State Medical License 1998 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Start of enrollment: 2009 Sep 01
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsRandomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.Aaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, David J Kwiatkowski, Shiven Patel
Lung Cancer. 2024-09-01 - 1 citationsRandomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins
Journal of Clinical Oncology. 2024-06-10 - 3 citationsAssessment of minimum target dose as a predictor of local failure after spine SBRT.Roman O Kowalchuk, Trey C Mullikin, Grant M Spears, Benjamin A Johnson-Tesch, Peter S Rose
Radiotherapy and Oncology. 2024-06-01
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
